E70.1 Other hyperphenylalaninemias

Name of the Condition

• Other hyperphenylalaninemias (ICD-10 Code: E70.1)

Summary

Other hyperphenylalaninemias are a group of rare genetic disorders characterized by elevated levels of phenylalanine in the blood, distinct from classical phenylketonuria. These conditions result from defects in enzymes or pathways involved in phenylalanine metabolism, leading to potential neurological and developmental complications if untreated. Early identification and management are important to mitigate long-term effects.

Causes

These disorders are caused by genetic mutations affecting enzymes or cofactors in the phenylalanine metabolic pathway. Mutations may impair the breakdown of phenylalanine or its conversion to other compounds, resulting in its accumulation. Inheritance patterns vary, with some forms following autosomal recessive transmission.

Risk Factors

• Genetic predisposition; family history of metabolic disorders.
• Consanguinity (parents who are close relatives).
• Certain ethnic groups with higher carrier rates for specific mutations.

Symptoms

• Neurological issues, such as developmental delay, intellectual disability, or seizures.
• Behavioral changes, including irritability or hyperactivity.
• Physical symptoms like skin rashes or musty body odor (less common than in classical phenylketonuria).
• Growth retardation or failure to thrive in severe cases.

Diagnosis

Diagnosis typically involves newborn screening for elevated phenylalanine levels. Confirmatory testing includes genetic analysis to identify specific mutations and measurement of phenylalanine metabolites. Additional biochemical tests may assess enzyme activity or cofactor levels to determine the underlying cause.

Treatment Options

Management focuses on dietary modifications to limit phenylalanine intake, often with specialized medical formulas. Some forms may respond to cofactor supplementation (e.g., tetrahydrobiopterin) to enhance residual enzyme activity. Regular monitoring of phenylalanine levels and nutritional status is essential.

Prognosis and Follow-Up

Prognosis depends on the specific subtype, severity, and timeliness of treatment. Early intervention can prevent or reduce neurological damage. Lifelong follow-up is recommended to monitor growth, developmental progress, and metabolic control, with adjustments to diet or therapy as needed.

Complications

• Neurological damage, including intellectual disability or seizures, if untreated.
• Growth delays or nutritional deficiencies from restrictive diets.
• Potential for psychosocial challenges related to chronic management.

Lifestyle & Prevention

• Adherence to a phenylalanine-restricted diet, guided by a metabolic specialist or dietitian.
• Regular monitoring of blood phenylalanine levels to maintain target ranges.
• Avoidance of high-protein foods and certain artificial sweeteners containing phenylalanine.

When to Seek Professional Help

Seek immediate medical attention for symptoms like seizures, significant developmental regression, or unexplained irritability. Routine follow-up with a metabolic specialist is necessary to adjust treatment and monitor for complications.

Tips for Medical Coders

Document the specific subtype of hyperphenylalaninemia (e.g., BH4 deficiency, dihydropteridine reductase deficiency) when available, as this may influence coding specificity. Ensure documentation supports the diagnosis and any associated complications or treatments. Note that E70.1 is used for hyperphenylalaninemias not classified elsewhere, so confirm no more specific code applies.